EXEL · Exelixis
AI read · Good for EXEL
The AI's read
The reported sales growth and profit show the existing Cabometyx business is bringing in more money. Exelixis also reported $1.4 billion in cash and investments, which can support its drug-development work. The estimate that sales deductions will reach about 30% means some drug sales will not become company income. Zanzalintinib still needs successful trials and approvals, so its hoped-for role as another major drug is not assured. Current sales and profit are already reported, so they carry more weight.